

## POWER OF ATTORNEY TO PROSECUTE APPLICATIONS BEFORE THE USPTO

I hereby revoke all previous powers of attorney given in the application identified in the attached SCHEDULE A under 37 CFR 3.73(b).

I hereby appoint:

☒ Practitioner associated with the Customer Number: 46037

OR

☐ Practitioner(s) named below (if more than ten patent practitioners are to be named, then a customer number must be used):

Name	Registration Number	Name	Registration Number

as attorney(s) or agent(s) to represent the undersigned before the United States Patent and Trademark Office (USPTO) in connection with any and all patent applications assigned only to the undersigned according to the USPTO assignment records or assignment documents attached to this form in accordance with 37 CFR 3.73(b).

Please change the correspondence address for the application identified in the attached statement under 37 CFR 3.73(b) to:

☒ The address associated with Customer Number: 46037

OR

☒ Firm or Individual Name Peter F. Corless  
EDWARDS ANGELL PALMER & DODGE LLP

Address P.O. Box 55874

City	Boston	State	MA	Zip	02205
Country	US	Telephone	(617) 239-0100	Email	pcorless@eapdlaw.com

Assignee Name and Address:

Government of the United States of America,  
as represented by the Secretary, Department of Health and Human Services  
6011 Executive Boulevard  
Suite 325  
Rockville, Maryland 20852

A copy of this form, together with a statement under 37 CFR 3.73(b) (Form PTO/SB/96 or equivalent) is required to be filed in each application in which this form is used. The statement under 37 CFR 3.73(b) may be completed by one of the practitioners appointed in this form if the appointed practitioner is authorized to act on behalf of the assignee, and must identify the application in which this Power of Attorney is to be filed.

### SIGNATURE of Assignee of Record

The individual whose signature and title is supplied below is authorized to act on behalf of the assignee

Signature	Date <span style="border: 1px solid black; padding: 2px 20px;">September 9, 2009</span>
Name <span style="border: 1px solid black; padding: 2px 20px;">Jasbir Kindra</span>	Telephone <span style="border: 1px solid black; padding: 2px 20px;">(301) 435-5170</span>
Title <span style="border: 1px solid black; padding: 2px 20px;">Chief, General Medicine Branch</span>	

## SCHEDULE A

Docket No.	Filed	App. No.	Issued	Patent No.	Short Title
84254CIP(47992)	10/31/2005	11/263,657			PROTEIN ARGININE N-METHYLTRANSFERASE 2
84255(47992)	8/24/2006	11/467,080			PHARMACODYNAMIC ASSAYS
84310(47992)	2/12/2008	11/990,419			NEURONAL AVALANCHE ASSAY
84321(47992)	9/17/2008	11/629,560			WEST NILE VIRUSES WITH MUTATIONS IN THE 3' TERMINA
84330(47992)	7/9/2004	10/887,770			INFECTIOUS CLONE OF HUMAN PARVOVIRUS B19 AND METHO
84403(47992)	6/7/2006	10/582,006			MONOCLONAL ANTIBODIES THAT BIND OR NEUTRALIZE DENG
84404CON3(47992)	5/27/1994	08/250,802	2/6/2001	6,184,024	CHIMERIC AND/OR GROWTH-RESTRICTED FLAVIVIRUSES
84404CON4(47992)	8/18/2000	09/643,217	1/13/2004	6,676,936	CHIMERIC AND/OR GROWTH-RESTRICTED FLAVIVIRUSES
84405(47992)	11/21/2003	10/719,547	6/5/2007	7,226,602	DEVELOPMENT OF MUTATIONS USEFUL FOR ATTENUATING DE
84405CON(47992)	3/2/2009	12/396,376			DEVELOPMENT OF MUTATIONS USEFUL FOR ATTENUATING D
84405DIV(47992)	6/2/2006	11/446,050	7/14/2009	7,560,118	DEVELOPMENT OF MUTATIONS USEFUL FOR ATTENUATING D
84406(47992)	7/26/2002	10/207,745	9/21/2004	6,794,174	FULL-LENGTH INFECTIOUS CDNA CLONES OF TICK BORNE F
84409DIV(47992)	10/27/2005	11/260,773			INTRANASAL IMMUNICATION
84412(47992)	9/5/2003	10/656,721	4/28/2009	7,524,508	SUBGENOMIC REPLICONS OF THE FLAVIVIRUS DENGUE
84412CON(47992)	2/27/2009	12/394,822			SUBGENOMIC REPLICONS OF THE FLAVIVIRUS DENGUE
84475(47992)	7/19/2001	09/762,538	6/6/2006	7,056,734	DIFFERENTIATION OF NON-INSULIN PRODUCING CELLS
84475CON(47792)	4/7/2006	11/400,715			DIFFERENTIATION OF NON-INSULIN PRODUCING CELLS
84491(47992)	10/21/2004	10/970,840	4/14/2009	7,517,531	DENGUE TETRAVALENT VACCINE CONTAINING A COMMON 30
84491CON(47992)	3/4/2009	12/398,043			DENGUE TETRAVALENT VACCINE CONTAINING A COMMON 30
84493(47992)	3/2/2001	09/798,542	2/3/2004	6,685,948	REPLICATION-DEFECTIVE DENGUE VIRUSES THAT ARE REPL
84550(47992)	1/3/2008	11/630,147			SAFER ATTENUATED VIRUS VACCINES WITH MISSING OR DI

84551(47992)	11/21/2008	10/301,960			ERYTHROID PROGENITOR CELLS
84553(47992)	8/10/2007	11/596,296			METHODS RELATED TO THE TREATMENT OF NEURODEGENERAT
84554(47992)	7/12/2006	10/585,725			COMPOSITION FOR DETECTING THE RESPONSE OF RECTAL A
84620(47992)	4/1/2004	10/485,140	8/18/2009	7,576,050	GLP-1 EXENDIN-4 PEPTIDE ANALOGS AND USES THEREOF
84620CON(47992)	12/18/2008	12/317,042			GLP-1 EXENDIN-4 PEPTIDE ANALOGS AND USES THEREOF